The Mechanism of ApoEe4 Promoting the dysfunction of glymphatic system in ARIA

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600117528

Enrollment

Unknown

Registered

2026-01-26

Start date

2026-01-26

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

ApoEe4 carriers:None

Non-ApoEe4 allele carriers:None

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients with mild Alzheimer's disease (AD) who received Lecanemab treatment in our hospital; 2. Voluntary participation in the study and signing of the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe cardiac insufficiency (left ventricular ejection fraction <=65%), hepatic dysfunction, or renal impairment (creatinine clearance <=30 ml/min); 2. Patients with contraindications to MRI examination.

Design outcomes

Primary

Measure	Time frame
ALPS index;ARIA incidence;	—

Countries

China

Contacts

Public ContactGao Ling

The First Affiliated Hospital of Xi'an Jiaotong University

linggaomed@xjtufh.edu.cn+86 29 85324033

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026